Nabriva Therapeutics (DB:NTY) - Aktienkurs, Nachrichten und Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NTY Aktienübersicht

A biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections.

Über das Unternehmen

NTY grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	0/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Hat keine nennenswerte Marktkapitalisierung (€2M)

Negatives Eigenkapital

Aktien sind hochgradig illiquide

Hat weniger als 1 Jahr Cash Runway

+ 1 mehr Risiko

Nabriva Therapeutics plc Wettbewerber

Biofrontera

XTRA:B8FK

€18.0m

SynBiotic

DUSE:SBX

€34.8m

MPH Health Care

DB:93M1

€120.7m

Redx Pharma

DB:0RX

€65.0m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Nabriva Therapeutics
Historische Aktienkurse
Aktueller Aktienkurs	US$0.67
52-Wochen-Hoch	US$2.42
52-Wochen-Tief	US$0.52
Beta	1.64
11 Monat Veränderung	0%
3 Monate Veränderung	-1.48%
1 Jahr Veränderung	-69.77%
33 Jahre Veränderung	-99.29%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-99.84%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	NTY	DE Pharmaceuticals	DE Markt
7D	0%	-1.3%	0.9%
1Y	-69.8%	-14.6%	4.2%

Rendite im Vergleich zur Industrie: NTY unter dem Niveau der Branche German Pharmaceuticals, die im vergangenen Jahr eine Rendite von -20.1% erzielte.

Rendite vs. Markt: NTY hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 8.6 erzielte.

Preisvolatilität

Is NTY's price volatile compared to industry and market?
NTY volatility
NTY Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.5%
10% least volatile stocks in DE Market	2.5%

Stabiler Aktienkurs: NTYDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von NTY im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2005	39	H. Hogan	www.nabriva.com

Nabriva Therapeutics plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Nabriva Therapeutics im Vergleich zum Marktanteil des Unternehmens?
NTY grundlegende Statistiken
Marktanteil	€1.57m
Gewinn(TTM)	-€51.34m
Umsatz(TTM)	€27.56m

0.1x

Kurs-Umsatz-Verhältnis

0.0x

Kurs-Gewinn-Verhältnis

Ist NTY zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
NTY Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$29.56m
Kosten der Einnahmen	US$47.66m
Bruttogewinn	-US$18.11m
Sonstige Ausgaben	US$36.95m
Umsatz	-US$55.05m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-17.04
Bruttomarge	-61.26%
Nettogewinnspanne	-186.26%
Schulden/Eigenkapital-Verhältnis	-3.3%

Wie hat sich NTY auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company listing is no longer active

NTY Aktienübersicht

Belohnungen

Risikoanalyse

Nabriva Therapeutics plc Wettbewerber

XTRA:B8FK

€18.0m

DUSE:SBX

€34.8m

DB:93M1

€120.7m

DB:0RX

€65.0m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Nabriva Therapeutics plc Files Form 15

Nasdaq to Delist the Ordinary Shares of Nabriva Therapeutics

Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index

Nabriva Therapeutics Receives A Delisting Determination Letter from Nasdaq

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc announced delayed 10-Q filing

Recent updates

Nabriva Therapeutics plc Files Form 15

Nasdaq to Delist the Ordinary Shares of Nabriva Therapeutics

Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index

Nabriva Therapeutics Receives A Delisting Determination Letter from Nasdaq

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc announced delayed 10-Q filing

Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer

Nabriva Therapeutics plc Announces Positive Topline Results from Phase 1 Trial of XENLETA (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Nabriva Therapeutics plc Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q2, 2022 Results on Aug 03, 2022

Nabriva Therapeutics plc, Annual General Meeting, Aug 11, 2022

The Nasdaq Stock Market LLC Approves Nabriva Therapeutics' Transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2021)

Nabriva Therapeutics plc to Report Q1, 2022 Results on May 05, 2022

No longer forecast to breakeven

Nabriva Therapeutics plc Announces First Patient Enrolled in Phase 1 Trial of Xenleta® (Lefamulin) in Adult Patients with Cystic Fibrosis

No longer forecast to breakeven

Forecast to breakeven in 2024

CEO & Director recently bought €51k worth of stock

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.90 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.29 loss per share (vs US$1.37 loss in 2Q 2020)

Independent Director George Talbot has left the company

Less than half of directors are independent

No longer forecast to breakeven

Sinovant Sciences and Nabriva Therapeutics plc Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

First quarter 2021 earnings released: US$0.53 loss per share (vs US$2.46 loss in 1Q 2020)

Nabriva Therapeutics plc has completed a Follow-on Equity Offering in the amount of $33.7 million.

Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)

Chief Financial Officer has left the company

Nabriva Therapeutics Appoints Steven Gelone to Its Board of Directors

Revenue beats expectations

Full year 2020 earnings released: US$5.41 loss per share (vs US$11.15 loss in FY 2019)

Nabriva Therapeutics plc to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: €1.63

Nabriva Therapeutics plc Announces A Hearing on May 14, 2021

Nabriva Therapeutics plc Announces the Publication of A Study Documenting the High Rates of Macrolide-Resistant Streptococcus Pneumoniae Throughout the United States

Nabriva Therapeutics Announces Retirement of Gary Sender as Chief Financial Officer, Effective as of March 12, 2021

Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China

New 90-day low: €3.05

New 90-day low: €3.18

New 90-day low: €0.32

Revenue beats expectations

Third quarter 2020 earnings released: US$0.09 loss per share

Nabriva Therapeutics plc to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €0.43

Nabriva Therapeutics plc Announces XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)

New 90-day low: €0.44

New 90-day low - €0.49

New 90-day low - €0.53

Earnings released

Nabriva Therapeutics plc to Report Q2, 2020 Results on Aug 06, 2020

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Nabriva Therapeutics plc's Grundlagenzusammenfassung

0.1x

0.0x

Erträge & Einnahmen